Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

2(33.3%)

6Total

Phase 1(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00531466Phase 2Terminated

Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury

Role: lead

NCT00532532Phase 2Terminated

Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis

Role: lead

NCT00576277Phase 1Completed

Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain

Role: lead

NCT00456560Phase 1Completed

AV650 Drug-Drug Interaction Study

Role: lead

NCT00076557Phase 1Terminated

Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B

Role: lead

NCT00364039Phase 1Completed

Study to Examine the Safety, Tolerability, and Pharmacokinetics of AV650

Role: lead

All 6 trials loaded